Key result
This review outlines current practices and future perspectives for atrial fibrillation prevention, focusing on antiarrhythmic drugs, catheter ablation, and hybrid therapies.
This review outlines current practices and future perspectives for the prevention of recurrent atrial fibrillation, including antiarrhythmic drugs, catheter ablation, and hybrid therapies.
Inconsistent AAD efficacy and safety limit rhythm control options in symptomatic AF; leaves open need for safer alternatives in trials and practice.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and represents a significant health care issue. The diagnosis and management of AF uses a significant proportion of the health care budget and is responsible for substantial morbidity and mortality. Restoration and maintenance of sinus rhythm is still an important treatment option for symptomatic AF. Anti-arrhythmic drugs (AADs) have had inconsistent results for the prevention of recurrent AF and have been hampered by significant adverse effects. Catheter ablation has rapidly evolved and is fast becoming an alternative for AF prevention. Although multiple treatment options exist, no single modality is effective for all patients. This review outlines best current practice for AF prevention and future perspectives, focusing on new and promising developments in antiarrhythmic drug therapy, strategies for ablation therapy, and forms of hybrid therapy that may offer improved outcomes in selected patients.
No takes yet. Share an insight, caveat, or question.
Govindan et al. (2010) conducted a review in Atrial fibrillation. AF prevention strategies (antiarrhythmic drugs, catheter ablation, hybrid therapy) was evaluated. This review outlines current practices and future perspectives for atrial fibrillation prevention, focusing on antiarrhythmic drugs, catheter ablation, and hybrid therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: